TORONTO, Dec. 21,
2022 /CNW/ - December 21, 2022 – Think
Research Corporation (TSXV: THNK) ("Think" or the
"Company"), a company focused on transforming healthcare
through integrated digital health software solutions, today
announced that it has granted 246,485 restricted share units (each,
an "RSU") to a key employee of the Company pursuant to the
Company's Omnibus Equity Incentive Plan ("OEIP"). 146,485 of
the RSUs will vest one year from today's date, and 100,000 will
vest two years from today's date. Each RSU represents the right to
receive, once vested, one Common Share. Further, the Company
also announced that it has granted 1,060,000 stock options (each,
an "Option") to key employees of the Company pursuant to the
Company's OEIP. The Options will vest ⅓ annually over three years
from December 21, 2022.
About Think Research Corporation
Think Research Corporation is an industry leader in delivering
knowledge-based digital health software solutions. The Company's
focused mission is to organize the world's health knowledge so
everyone gets the best care. Its evidence-based healthcare
technology solutions support the clinical decision-making process,
standardize care, to facilitate better health care outcomes. The
Company gathers, develops, and delivers knowledge-based solutions
globally to customers which typically includes enterprise clients,
hospitals, health regions, healthcare professionals, and / or
governments. The Company has gathered a significant amount of data
by building its repository of knowledge through its network and
group of companies, including acquired companies.
Think licenses its solutions to over 13,000 facilities for over
300,000 primary care, acute care, and long-term care doctors,
nurses and pharmacists that rely on the content and data provided
by Think to support their practices. Millions of patients and
residents annually receive better care due to the essential data
that Think produces, manages and delivers.
In addition, the Company collects and manages pharmaceutical and
clinical trial data via the BioPharma Services entity that Think
acquired on September 10, 2021.
BioPharma Services is a leading provider of bioequivalence and
Phase 1 clinical research services to pharmaceutical companies
globally. Think's other services include a network of digital-first
primary care clinics and medical clinics that provide elective
surgery. Visit: www.thinkresearch.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibilities for the adequacy or
accuracy of this release.
For more
information: https://www.thinkresearch.com/ca/investors/
SOURCE Think Research Corporation